Oxford
Gene Technology (OGT), provider of innovative
clinical genetics and diagnostic solutions to advance molecular medicine, will be exhibiting and presenting its biomarker discovery
service at the
Molecular Medicine Tri-Con in San Francisco,
California (19
th-23
rd February 2012). The conference, organized by the Cambridge Healthtech
Institute, will include an OGT presentation entitled
"Integrated Biomarker Discovery: Multi-Method Approach to Enable Early
Biomarker Success", taking place on
Tuesday 21st February at
15.50 in the Moscone North Convention Centre. The talk, given by Dr Graham Speight, Head
of Genomic Biomarkers at OGT, will explain how high-throughput biomarker
discovery can generate rich datasets identifying a number of biologically
relevant disease markers, making it useful for validation, proof of concept and
in depth analysis.
Will Colón, OGT's Business Development Director, Biomarker
Discovery, commented: "OGT's expertise in genomic- and protein- based arrays
makes us ideally placed to offer a powerful, integrated range of biomarker
discovery solutions. As well as DNA arrays, we have developed a unique
"functional protein" array technology, which conserves the
in vivo
conformation of each protein when attached to the surface of the array. This
enables the discovery of autoantibody biomarkers with maximum sensitivity and
specificity. Utilising our high-throughput workflow procedures, and over 140
quality control steps, our biomarker discovery service uses only the minimum
amount of precious clinical sample necessary to produce insightful results."
As
well as exhibiting and presenting at the conference, OGT will also provide
details of its Genefficiency
TM genomic products and
services as part of
the Molecular Medicine Tri-Con product showcase. This will include OGT's Targeted Sequencing Service, which is designed to
provide meaningful results rather than insurmountable data sets, achieved via
OGT's internationally recognised probe design, data analysis expertise and
independently- accredited quality control procedures. This service has recently
been extended to cover the genomic analysis of rare diseases, providing an option
specifically optimised to help investigators and clinicians identify causative
mutations quickly, easily and without the need for in-house practical or
bioinformatics expertise.
OGT has recently infused
some of its expertise on biomarkers into a white paper entitled "Autoantibody
biomarker panels for improved disease diagnosis". This can be downloaded from the OGT website and will also be freely available as
a hard copy at OGT's booth (# 506), where OGT experts
will also be on hand to discuss how they can help with your biomarker discovery programme, adding value from concept to completion.
To
find out more about the full range of products and services offered by OGT,
visit
www.ogt.co.uk.
Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!
Request your free copies HERE
Popular this Month
Top 10 most popular articles this month
Today's Picks
Looking for a Supplier?
Search by company or by product
Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.
Lab Bulletin is published by newleaf marketing communications ltd.